These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18391605

  • 21. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
    Ansari MS, Gupta NP.
    Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
    [Abstract] [Full Text] [Related]

  • 22. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
    Amato RJ, Teh BS, Henary H, Khan M, Saxena S.
    Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
    [Abstract] [Full Text] [Related]

  • 23. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
    Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM.
    Cancer; 2006 Jul 15; 107(2):266-74. PubMed ID: 16779800
    [Abstract] [Full Text] [Related]

  • 24. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.
    J Urol; 2007 Dec 15; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K, Vaculikova M, Dolezel M, Petera J, Moravek P, Prosvic P, Zoul Z, Vosmik M, Dolezal J, Simakova E.
    Oncol Rep; 2005 Oct 15; 14(4):1077-81. PubMed ID: 16142375
    [Abstract] [Full Text] [Related]

  • 27. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
    Sasaki T, Nakamura K, Ogawa K, Onishi H, Okamoto A, Koizumi M, Shioyama Y, Mitsumori M, Teshima T, Japanese Patterns of Care Study Working Subgroup on Prostate Cancer.
    BJU Int; 2009 Nov 15; 104(10):1462-6. PubMed ID: 19522869
    [Abstract] [Full Text] [Related]

  • 28. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM, Radiation Therapy Oncology Group Trial 9902.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):672-8. PubMed ID: 18990504
    [Abstract] [Full Text] [Related]

  • 29. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF, Kalofonos H, Adamou A, Kosmides P, Skarlos D, Aravantinos G, Kiamouris C, Adimchi O, Fountzilas G, Dimopoulos AM.
    Urology; 2005 Aug 01; 66(2):382-5. PubMed ID: 16098366
    [Abstract] [Full Text] [Related]

  • 30. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ.
    J Clin Oncol; 1999 Jun 01; 17(6):1664-71. PubMed ID: 10561202
    [Abstract] [Full Text] [Related]

  • 31. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
    Hoshi S, Ohyama C, Namiki S, Hagisawa S, Satoh M, Saito S, Ono K, Shirasaka T, Arai Y.
    Gan To Kagaku Ryoho; 2002 Oct 01; 29(10):1773-8. PubMed ID: 12402428
    [Abstract] [Full Text] [Related]

  • 32. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 33. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY, Chi KN.
    Can J Urol; 2006 Dec 07; 13(6):3335-9. PubMed ID: 17187697
    [Abstract] [Full Text] [Related]

  • 34. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
    Small EJ, Fippin LJ, Whisenant SP.
    Cancer Invest; 1998 Dec 07; 16(7):456-61. PubMed ID: 9774952
    [Abstract] [Full Text] [Related]

  • 35. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G.
    Cancer Treat Rev; 2008 Dec 07; 34(8):710-8. PubMed ID: 18620815
    [Abstract] [Full Text] [Related]

  • 36. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
    Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ.
    Cancer; 2000 Feb 15; 88(4):825-34. PubMed ID: 10679652
    [Abstract] [Full Text] [Related]

  • 37. [High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].
    Kattan J, Droz JP, Culine S.
    Bull Cancer; 1993 Mar 15; 80(3):248-54. PubMed ID: 8173177
    [Abstract] [Full Text] [Related]

  • 38. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.
    Serretta V, Altieri V, Morgia G, Siragusa A, De Grande G, Napoli M, Falsaperla M, Melloni D, Allegro R.
    Urol Int; 2009 Mar 15; 83(4):452-7. PubMed ID: 19996654
    [Abstract] [Full Text] [Related]

  • 39. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun 15; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 40. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.
    BJU Int; 2009 Nov 15; 104(9):1208-14. PubMed ID: 19388987
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.